✨ Onyx Summary Keros Therapeutics announced a strategic realignment to focus resources on its lead program, KER-065, and discontinue internal development of cibotercept following Phase 2 data in pulmonary arterial hypertension. The company also implemented board and leadership changes, including appointing Jean-Jacques Bienaimé as Chair and promoting Lorena Lerner, Ph.D.
✨ Onyx Summary Adverum Biotechnologies announced that CEO Laurent Fischer, M.D., and Board Member Szilárd Kiss, M.D., will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. The discussion will be webcast live, offering insights into Adverum’s intravitreal
✨ Onyx Summary Geron Corporation appointed Harout Semerjian as President and Chief Executive Officer, effective August 7, 2025, succeeding Interim CEO Dawn Carter Bir, who will remain on the Board of Directors. Semerjian, a 30-year hematology and oncology veteran with leadership roles at Novartis, Ipsen, and GlycoMimetics, joins Geron as it
✨ Onyx Summary The American Cancer Society announced a new partnership with Guardant Health to expand nationwide cancer screening initiatives, including public awareness campaigns, community-based interventions, and state-level coalition work to remove barriers to care. By combining ACS’s reach with Guardant’s innovation, the collaboration aims to close persistent screening
✨ Onyx Summary Verily announced the continuation of its partnership with Vanderbilt University Medical Center to support the NIH’s All of Us Research Program, extending its role in powering the Researcher Workbench platform that now serves over 17,000 researchers across 1,100 organizations worldwide. By enhancing secure, cloud-based access
✨ Onyx Summary Affinia Therapeutics has partnered with the DCM Foundation and the Genetic Cardiomyopathy Awareness Consortium to raise awareness of BAG3 dilated cardiomyopathy (DCM) and drive early genetic testing for this life-threatening heart disease. The collaboration underscores the growing role of precision medicine in cardiovascular care and highlights Affinia’s
✨ Onyx Summary Verily announced it has received a $14.7M grant from The Michael J. Fox Foundation to generate one of the most comprehensive molecular datasets for Parkinson’s disease, leveraging biospecimens and multimodal data from the Personalized Parkinson’s Project. By making this resource publicly available through its Workbench
✨ Onyx Summary Verily announced new institutions adopting its Workbench platform—including NashBio, the University of Oxford, and NIH’s CARD program—while rolling out enhanced tools for data governance, analysis, and discovery. As biomedical data grows exponentially, these expansions position Workbench as a key infrastructure for harnessing complex datasets, enabling
✨ Onyx Summary Mongoose Bio, a Houston-based clinical-stage biotech developing next-generation precision TCR-T therapies for solid tumors, was named one of the top 10 most promising companies at the 13th Annual Texas Life Science Forum. The recognition highlights growing investor and scientific confidence in Mongoose Bio’s pioneering T-cell platform, marking
